Exact Sciences Corporation

Hi, we're about to begin. Good afternoon, ladies and gentlemen, and welcome to the Exact Sciences third quarter 2023 earnings conference call. At this time, all participants are in the listen-only mode, and please be advised that this call is being recorded. After the speakers prepare to march, there will be a question and answer session. If you would like to ask a question during this time, simply press star 1 on your telephone keypad. If you would like to withdraw your question, simply press star 1 again. And now at this time, I would like to turn the call over to Mr. Eric Holset, Manager of Investor Relations. Please go ahead, sir.

Thanks, Beau. Thank you for joining us for ExactScience's third quarter 2023 conference call. On the call today are Kevin Conroy, the company's Chairman and CEO, and Jeff Elliott, our Chief Financial Officer. Everett Cunningham, our Chief Commercial Officer, will also be available for questions. ExactScience issued a news release earlier this afternoon detailing our third quarter financial results. This news release and today's presentation are available on our website at exactsciences.com. During today's call, we will make forward-looking statements based on current expectations. Our actual results may be materially different from such statements. Discussions of non-GAAP figures and reconciliations to GAAP figures are available in our earnings press release, and descriptions of the risks and uncertainties associated with Exact Sciences are included in our SEC filings. Both can be accessed through our website. I'll now turn the call over to Kevin.

Thank you, Eric. Our third quarter results reflect our commitment to help eradicate cancer with tests that prevent it, detect it earlier, and guide its treatment. Cologuard and Ocotype DX fuel our growing $2.5 billion business and the next wave of breakthrough cancer diagnostic innovations. Our focus on solving the needs of patients and healthcare providers powered outstanding third quarter results allowing us to raise our 2023 guidance for both revenue and adjusted EBITDA. Highlights from the third quarter include delivering more than 1 million total tests, including a record number of Cologuard and Oncotype DX results. Growing core revenue of 23% to 625 million, also a record. generating 56 million of adjusted EBITDA, a $69 million improvement. Exceeding 1 million people screened with Cologuard between ages 45 and 49 in the two and a half years since the recommended start age was moved from 50 to 45. Expanding the impact of Oxide DX by launching in Japan on a reimbursed basis. Beginning to integrate resolution biosciences and our new liquid therapy selection test into our portfolio. Presenting pivotal Blue Sea study results at the American College of Gastroenterology Conference, demonstrating next generation Cologuard met all endpoints. And showcasing the breadth and depth of our research with five abstracts with our precision oncology and multi-cancer tests at the European Society of Medical Oncology Congress. The investments we've made in our core business are returning sustainable revenue growth and margin expansion. This allows us to strengthen our world-class team and develop new, life-changing solutions for our patients. Jeff will now review our third quarter results.